T1	intervention 0 11	Trastuzumab
T2	total-participants 670 674	1694
T3	eligibility 43 70	HER2-positive breast cancer
T5	intervention-participants 743 747	1694
T6	control-participants 795 799	1693
T7	control 818 829	observation
T8	cv-bin-abs 1163 1166	220
T9	iv-bin-abs 1123 1126	127
T11	outcome 1473 1507	disease-free survival at two years
T14	outcome 1534 1550	Overall survival
T15	iv-bin-abs 1602 1604	29
T16	cv-bin-abs 1633 1635	37
T17	outcome 1655 1676	Severe cardiotoxicity
T18	iv-bin-percent 1690 1701	0.5 percent
T4	outcome 996 1002	events
T10	outcome 1605 1611	deaths
T12	outcome 1004 1106	recurrence of breast cancer, contralateral breast cancer, second nonbreast malignant disease, or death
